Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
215 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2014', provides an overview of the Duchenne Muscular Dystrophy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Duchenne Muscular Dystrophy Overview 8 Therapeutics Development 9 Pipeline Products for Duchenne Muscular Dystrophy - Overview 9 Pipeline Products for Duchenne Muscular Dystrophy - Comparative Analysis 10 Duchenne Muscular Dystrophy - Therapeutics under Development by Companies 11 Duchenne Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 15 Duchenne Muscular Dystrophy - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Duchenne Muscular Dystrophy - Products under Development by Companies 19 Duchenne Muscular Dystrophy - Products under Investigation by Universities/Institutes 23 Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development 24 Sanofi 24 Eli Lilly and Company 25 Daiichi Sankyo Company, Limited 26 Nippon Shinyaku Co., Ltd. 27 Zambon Company S.p.A. 28 Sarepta Therapeutics, Inc. 29 NicOx S.A. 30 Lexicon Pharmaceuticals, Inc. 31 Galapagos NV 32 Summit Corporation plc 33 Santhera Pharmaceuticals Holding AG 34 Shenzhen Beike Biotechnology Co., Ltd. 35 Italfarmaco S.p.A. 36 Acceleron Pharma, Inc. 37 Prosensa Holding B.V. 38 Catabasis Pharmaceuticals, Inc. 39 Nobelpharma Co., Ltd. 40 PTC Therapeutics, Inc. 41 Reata Pharmaceuticals, Inc. 42 Fate Therapeutics, Inc. 43 N-Gene Research Laboratories, Inc. 44 Asklepios BioPharmaceutical, Inc. 45 Genethon 46 miRagen Therapeutics, Inc. 47 Prosensa Therapeutics B.V. 48 Tarix Pharmaceuticals LTD. 49 EryDel SPA 50 Myomics, Inc. 51 Prothelia, Inc. 52 ReveraGen BioPharma, Inc. 53 Retrophin, LLC 54 Duchenne Muscular Dystrophy - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 61 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 70 ataluren - Drug Profile 70 drisapersen - Drug Profile 73 tadalafil - Drug Profile 75 idebenone - Drug Profile 77 eteplirsen - Drug Profile 80 givinostat - Drug Profile 82 PRO-045 - Drug Profile 84 CRD-007 - Drug Profile 86 halofuginone hydrobromide Delayed Release - Drug Profile 87 arbekacin - Drug Profile 89 PRO-044 - Drug Profile 90 PRO-053 - Drug Profile 92 NU-21101 + NU-21502 - Drug Profile 93 AAV1-FS-344 - Drug Profile 94 SMTC-1100 - Drug Profile 95 GLPG-0492 - Drug Profile 97 Biostrophin - Drug Profile 98 dexamethasone - Drug Profile 99 CAT-1004 - Drug Profile 101 Stem Cell Therapy for Duchenne Muscular Dystrophy - Drug Profile 103 NS-065 - Drug Profile 104 LX-2931 - Drug Profile 105 SRP-4050 - Drug Profile 107 naproxcinod - Drug Profile 108 TXA-127 - Drug Profile 110 BGP-15 - Drug Profile 112 MGN-8107 - Drug Profile 114 PRO-052 - Drug Profile 115 PRO-055 - Drug Profile 116 Gene Therapy For Duchenne Muscular Dystrophy - Drug Profile 117 Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 118 PRT-01 - Drug Profile 119 PRT-20 - Drug Profile 121 VBP-15 - Drug Profile 122 RE-001 - Drug Profile 124 CAT-1040 - Drug Profile 125 poloxamer - Drug Profile 126 Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile 127 RTC-13 - Drug Profile 129 SRP-4045 - Drug Profile 131 RTC-14 - Drug Profile 132 Gene Therapy Targeting Dysferlin for Duchenne Muscular Dystrophy and Muscular Dystrophy - Drug Profile 133 Small Molecule to Activate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 134 SRP-4053 - Drug Profile 135 ARM-210 - Drug Profile 136 Recombinant Protein for Muscular Dystrophy - Drug Profile 137 Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 138 GsMTx-4 - Drug Profile 139 Aptamer Targeting Calcineurin A for Genetic Disorders and Musculoskeletal - Drug Profile 141 Peptides for Duchenne Muscular Dystrophy and Cardiac Disease - Drug Profile 142 CAT-1041 - Drug Profile 143 MG-53 - Drug Profile 144 NBD Peptide - Drug Profile 146 SRP-4044 - Drug Profile 148 TALENs - Drug Profile 149 ACE-083 - Drug Profile 150 Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy - Drug Profile 151 PRT-300 - Drug Profile 152 PRT-400 - Drug Profile 153 PRT-500 - Drug Profile 154 Antisense Oligonucleotide for Duchenne Muscular Dystrophy - Drug Profile 155 Small Molecules to Modulate Utrophin for Duchenne Muscular Dystrophy - Drug Profile 156 Small Molecule for Duchenne Muscular Dystrophy - Drug Profile 157 PROSPECT - Drug Profile 158 ZP-049 - Drug Profile 159 SRP-4052 - Drug Profile 160 SRP-4055 - Drug Profile 161 Next Generation Utrophin Modulator - Drug Profile 162 SRP-4008 - Drug Profile 163 Duchenne Muscular Dystrophy - Recent Pipeline Updates 164 Duchenne Muscular Dystrophy - Dormant Projects 198 Duchenne Muscular Dystrophy - Discontinued Products 199 Duchenne Muscular Dystrophy - Product Development Milestones 200 Featured News & Press Releases 200 Appendix 209 Methodology 209 Coverage 209 Secondary Research 209 Primary Research 209 Expert Panel Validation 209 Contact Us 210 Disclaimer 210
List of Tables Number of Products under Development for Duchenne Muscular Dystrophy, H2 2014 14 Number of Products under Development for Duchenne Muscular Dystrophy - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Comparative Analysis by Early Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Development by Companies, H2 2014 (Contd..2) 26 Products under Development by Companies, H2 2014 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2014 28 Duchenne Muscular Dystrophy - Pipeline by Sanofi, H2 2014 29 Duchenne Muscular Dystrophy - Pipeline by Eli Lilly and Company, H2 2014 30 Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 31 Duchenne Muscular Dystrophy - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 32 Duchenne Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2014 33 Duchenne Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2014 34 Duchenne Muscular Dystrophy - Pipeline by NicOx S.A., H2 2014 35 Duchenne Muscular Dystrophy - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 36 Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2014 37 Duchenne Muscular Dystrophy - Pipeline by Summit Corporation plc, H2 2014 38 Duchenne Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2014 39 Duchenne Muscular Dystrophy - Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H2 2014 40 Duchenne Muscular Dystrophy - Pipeline by Italfarmaco S.p.A., H2 2014 41 Duchenne Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2014 42 Duchenne Muscular Dystrophy - Pipeline by Prosensa Holding B.V., H2 2014 43 Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 44 Duchenne Muscular Dystrophy - Pipeline by Nobelpharma Co., Ltd., H2 2014 45 Duchenne Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2014 46 Duchenne Muscular Dystrophy - Pipeline by Reata Pharmaceuticals, Inc., H2 2014 47 Duchenne Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H2 2014 48 Duchenne Muscular Dystrophy - Pipeline by N-Gene Research Laboratories, Inc., H2 2014 49 Duchenne Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 50 Duchenne Muscular Dystrophy - Pipeline by Genethon, H2 2014 51 Duchenne Muscular Dystrophy - Pipeline by miRagen Therapeutics, Inc., H2 2014 52 Duchenne Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H2 2014 53 Duchenne Muscular Dystrophy - Pipeline by Tarix Pharmaceuticals LTD., H2 2014 54 Duchenne Muscular Dystrophy - Pipeline by EryDel SPA, H2 2014 55 Duchenne Muscular Dystrophy - Pipeline by Myomics, Inc., H2 2014 56 Duchenne Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2014 57 Duchenne Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2014 58 Duchenne Muscular Dystrophy - Pipeline by Retrophin, LLC, H2 2014 59 Assessment by Monotherapy Products, H2 2014 60 Assessment by Combination Products, H2 2014 61 Number of Products by Stage and Target, H2 2014 64 Number of Products by Stage and Mechanism of Action, H2 2014 68 Number of Products by Stage and Route of Administration, H2 2014 71 Number of Products by Stage and Molecule Type, H2 2014 74 Duchenne Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H2 2014 169 Duchenne Muscular Dystrophy - Dormant Projects, H2 2014 203 Duchenne Muscular Dystrophy - Discontinued Products, H2 2014 204
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
